All In Biotech

Drug Trial Radar · NCT00585975

Efficacy and Safety of Bromfenac Ophthalmic Solution

Last checked: Nov 20, 2026Latest source record: Feb 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 568 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

568

Actual

Start

Oct 2007

Primary completion

Jul 2008

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Jan 4, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a safety and efficacy study of bromfenac ophthalmic solution

Conditions

  • Cataract Surgery

Interventions

  • bromfenac ophthalmic solutionDrug

    sterile opthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Summed Ocular Inflammation Score (SOIS) of ZeroTime frame: Day 15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ISTA Pharmaceuticals, Inc.

    Irvine, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.